A proposal for radical changes in the drug-approval process

New England Journal of Medicine

Volumn 355, Issue 6, 2006, Pages 618-623

  Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALZHEIMER DISEASE; DRUG APPROVAL; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEART DISEASE; HEART INFARCTION PREVENTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; STROKE; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS; DRUG APPROVAL; DRUG DESIGN; DRUG EVALUATION; HUMANS; MORTALITY; PATENTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33746872608     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsb055203     Document Type: Review

References (16)

1. Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House, 2004.
2. Avorn J. FDA standards - good enough for government work? N Engl J Med 2005;353:969-72.
3. Wood AJ. The safety of new medicines: the importance of asking the right questions. JAMA 1999;281:1753-4.
4. Wood AJ, Stein CM, Woosley R. Making medicines safer - the need for an independent drug safety board. N Engl J Med 1998;339:1851-4.
5. DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001;69:297-307.
6. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
7. Reichert JM, Milne CP. Public and private sector contributions to the discovery and development of "impact" drugs. Am J Ther 2002;9:543-55.
8. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-9.
9. Mervis J. Productivity counts - but the definition is key. Science 2005;309:726.
10. Challenge and opportunity on the critical path to new medical products. Rockville, Md.: Food and Drug Administration, 2004. (Accessed June 7, 2006, at http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.)
11. Physicians' desk reference. 59th ed. Montvale, N.J.: Thomson PDR, 2005.
12. Barton JH, Emanuel EJ. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA 2005;294:2075-82.
13. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000;283:1967-75. [Erratum, JAMA 2002;288:2976.]
14. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. [Errata, JAMA 2003;289:178, 2004;291:2196.]
15. Roberts TG Jr, Chabner BA. Beyond fast track for drug approvals. N Engl J Med 2004;351:501-5.
16. Report on the performance of drug and biologics firms in conducting postmarketing commitment studies; availability. Fed Regist 2005;70(33):8379-81.